SCHEMBL21807136

SCHEMBL21807136

COC(=O)C(=[N+]=[N-])c1cc(F)c(F)c(Cl)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ CES2 O00748 1/20 0.34
▸ CES1 P23141 1/20 0.34
▸ TAS1R3 Q7RTX0 4/20 0.33
▸ TAS1R1 Q7RTX1 4/20 0.33
▸ TAS1R2 Q8TE23 4/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ CASP3 P42574 1/20 0.33
▸ SENP7 Q9BQF6 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ KCNQ3 O43525 4/20 0.32
▸ KCNQ2 O43526 4/20 0.32
▸ KCNE1 P15382 3/20 0.32
▸ KCNQ1 P51787 3/20 0.32
▸ KCNQ5 Q9NR82 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27153196 0.78 CES2 (0.42) ALDH1A1KDM4ECES2CES1MEN1
SCHEMBL29782139 0.77 HPGD (0.48) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL25108748 0.77 CES2 (0.37) ALDH1A1KDM4EGAACES2CES1
SCHEMBL25108905 0.77 CES2 (0.37) ALDH1A1KDM4EGAACES2CES1
SCHEMBL2651614 0.77 HPGD (0.48) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL23025106 0.76 KDM4E (0.50) ALDH1A1KDM4EGAACES2CES1
SCHEMBL14638925 0.73 TAS1R3 (0.38) ALDH1A1KDM4EGAATAS1R3TAS1R1
SCHEMBL926435 0.71 HPGD (0.44) ALDH1A1KDM4ECES2CES1MEN1
SCHEMBL27154482 0.71 RAB9A (0.44) ALDH1A1KDM4EGAACES2CES1
SCHEMBL6152817 0.71 CES2 (0.47) GAACES2MAPTHDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 — — US disclosed
EP-3852790-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X Forma Therapeutics, Inc. (US) 2021-07-28 — — EP disclosed
CN-113164571-A Inhibition of ubiquitin-specific peptidase 9X 福马治疗股份有限公司 2021-07-23 — — CN disclosed
WO-2020061261-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. (US) 2020-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X USP9X, USP19, USP39 ALDH1A1 1794/4885KDM4E 576/4885GAA 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback